
Kadmon Holdings, Inc. Net Income 2011-2026 | KDMN
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Kadmon Holdings, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -109 M | -61.4 M | -54.3 M | -79.8 M | -209 M | -147 M | -64.4 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -54.3 M | -209 M | -104 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
-24.2 M | $ 6.4 | - | $ 63.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
98.1 M | $ 21.41 | - | $ 1 B | ||
|
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | ||
|
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
-1.36 M | $ 0.9 | -2.33 % | $ 6.62 M | ||
|
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
226 M | $ 21.96 | - | $ 3.64 B | ||
|
Cardiff Oncology
CRDF
|
-45.9 M | $ 1.72 | - | $ 115 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | ||
|
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | ||
|
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | ||
|
Esperion Therapeutics
ESPR
|
-22.7 M | $ 1.91 | - | $ 397 M | ||
|
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | ||
|
Galectin Therapeutics
GALT
|
-30.8 M | $ 2.33 | - | $ 149 M | ||
|
Allakos
ALLK
|
-186 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-43.4 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | ||
|
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - | ||
|
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-10.3 M | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
-120 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-30.4 M | - | 17.91 % | $ 11.1 M | ||
|
BioNTech SE
BNTX
|
10.3 B | $ 105.46 | - | $ 27.2 B | ||
|
Heron Therapeutics
HRTX
|
-20.2 M | $ 1.19 | - | $ 198 M | ||
|
Avenue Therapeutics
ATXI
|
-2.91 M | - | -52.27 % | $ 4.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | ||
|
ImmuCell Corporation
ICCC
|
-1.04 M | $ 8.36 | - | $ 75.5 M | ||
|
Aquestive Therapeutics
AQST
|
-83.8 M | $ 4.08 | - | $ 436 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 23.26 | - | $ 2.96 B | ||
|
InflaRx N.V.
IFRX
|
-45.6 M | $ 1.48 | - | $ 152 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
-288 M | $ 1.44 | - | $ 383 M | ||
|
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | ||
|
Innate Pharma S.A.
IPHA
|
-52.8 M | $ 1.41 | - | $ 235 M | ||
|
AstraZeneca PLC
AZN
|
115 M | - | - | $ 96.9 B | ||
|
Jaguar Health
JAGX
|
-53.6 M | $ 0.39 | -0.18 % | $ 910 K | ||
|
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-9.83 M | $ 2.91 | - | $ 4.79 M | ||
|
KalVista Pharmaceuticals
KALV
|
-110 M | $ 19.63 | - | $ 1.06 B | ||
|
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | ||
|
Kamada Ltd.
KMDA
|
-2.23 M | $ 8.28 | - | $ 260 M | ||
|
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B |